Altimmune Advances Pemvidutide with FDA Breakthrough Designation and Phase 3 MASH Trial Planned
Mar 05, 2026
Altimmune's pemvidutide received FDA Breakthrough Therapy Designation for MASH treatment, with Phase 3 trial initiation planned for 2026. The company raised $75 million in January 2026 to fund development.